Clinical trial
Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in…
NCT00454909 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00454909 |
|---|---|
| Title | Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years. |
| Official title | Study to Assess Immunogenicity, Reactogenicity and Safety of 1 Dose of GSK Biologicals' Meningococcal Vaccine GSK134612 vs. 1 Dose of Sanofi-Pasteur's Menactra® in Healthy Subjects 10-25 Years. |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Infections, Meningococcal |
| Intervention type | Biological |
| Interventions | Meningococcal vaccine 134612, Menactra® |
| Enrollment | 873 |
| Start date | Apr 23, 2007 |
| Primary completion | Oct 31, 2007 |
| Completion | Apr 11, 2008 |
| First posted | Apr 2, 2007 |
| Last update posted | Jun 8, 2018 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- 1–9 Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: